Characterizing the outcomes of metastatic papillary renal cell carcinoma

John Connor Wells; Frede Donskov; Anna P. Fraccon; Felice Pasini; Georg A. Bjarnason; Benoit Beuselinck; Jennifer J. Knox; Sun Young Rha; Neeraj Agarwal; Isaac Alex Bowman; Jae Lyun Lee; Sumanta K. Pal; Sandy Srinivas; Douglas Scott Ernst; Ulka N. Vaishampayan; Lori A. Wood; Robin Simpson; Guillermo De Velasco; Toni K. Choueiri; Daniel Y.C. Heng

doi:10.1002/cam4.1048

Characterizing the outcomes of metastatic papillary renal cell carcinoma

John Connor Wells, Frede Donskov, Anna P. Fraccon, Felice Pasini, Georg A. Bjarnason, Benoit Beuselinck, Jennifer J. Knox, Sun Young Rha, Neeraj Agarwal, Isaac Alex Bowman, Jae Lyun Lee, Sumanta K. Pal, Sandy Srinivas, Douglas Scott Ernst, Ulka N. Vaishampayan, Lori A. Wood, Robin Simpson, Guillermo De Velasco, Toni K. Choueiri, Daniel Y.C. Heng

Department of Internal Medicine

Research output: Contribution to journal › Article › peer-review

28 Citations (Scopus)

Abstract

Outcomes of metastatic papillary renal cell carcinoma (pRCC) patients are poorly characterized in the era of targeted therapy. A total of 5474 patients with metastatic renal cell carcinoma (mRCC) in the International mRCC Database Consortium (IMDC) were retrospectively analyzed. Outcomes were compared between clear cell (ccRCC; n = 5008) and papillary patients (n = 466), and recorded type I and type II papillary patients (n = 30 and n = 165, respectively). Overall survival (OS), progression-free survival (PFS), and overall response rate (ORR) favored ccRCC over pRCC. OS was 8 months longer in ccRCC patients and the hazard ratio of death was 0.71 for ccRCC patients. No differences in PFS or ORR were detected between type I and II PRCC in this limited dataset. The median OS for type I pRCC was 20.0 months while the median OS for type II was 12.6 months (P = 0.096). The IMDC prognostic model was able to stratify pRCC patients into favorable risk (OS = 34.1 months), intermediate risk (OS = 17.0 months), and poor-risk groups (OS = 6.0 months). pRCC patient outcomes were inferior to ccRCC, even after controlling for IMDC prognostic factors. The IMDC prognostic model was able to effectively stratify pRCC patients.

Original language	English
Pages (from-to)	902-909
Number of pages	8
Journal	Cancer medicine
Volume	6
Issue number	5
DOIs	https://doi.org/10.1002/cam4.1048
Publication status	Published - 2017 May

Bibliographical note

Publisher Copyright:
© 2017 The Authors. Cancer Medicine published by John Wiley & Sons Ltd.

All Science Journal Classification (ASJC) codes

Oncology
Radiology Nuclear Medicine and imaging
Cancer Research

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.1002/cam4.1048

Cite this

Connor Wells, J., Donskov, F., Fraccon, A. P., Pasini, F., Bjarnason, G. A., Beuselinck, B., Knox, J. J., Rha, S. Y., Agarwal, N., Bowman, I. A., Lee, J. L., Pal, S. K., Srinivas, S., Scott Ernst, D., Vaishampayan, U. N., Wood, L. A., Simpson, R., De Velasco, G., Choueiri, T. K., & Heng, D. Y. C. (2017). Characterizing the outcomes of metastatic papillary renal cell carcinoma. Cancer medicine, 6(5), 902-909. https://doi.org/10.1002/cam4.1048

@article{02ecfa0033894e958ac5c8ff726d9fc2,

title = "Characterizing the outcomes of metastatic papillary renal cell carcinoma",

abstract = "Outcomes of metastatic papillary renal cell carcinoma (pRCC) patients are poorly characterized in the era of targeted therapy. A total of 5474 patients with metastatic renal cell carcinoma (mRCC) in the International mRCC Database Consortium (IMDC) were retrospectively analyzed. Outcomes were compared between clear cell (ccRCC; n = 5008) and papillary patients (n = 466), and recorded type I and type II papillary patients (n = 30 and n = 165, respectively). Overall survival (OS), progression-free survival (PFS), and overall response rate (ORR) favored ccRCC over pRCC. OS was 8 months longer in ccRCC patients and the hazard ratio of death was 0.71 for ccRCC patients. No differences in PFS or ORR were detected between type I and II PRCC in this limited dataset. The median OS for type I pRCC was 20.0 months while the median OS for type II was 12.6 months (P = 0.096). The IMDC prognostic model was able to stratify pRCC patients into favorable risk (OS = 34.1 months), intermediate risk (OS = 17.0 months), and poor-risk groups (OS = 6.0 months). pRCC patient outcomes were inferior to ccRCC, even after controlling for IMDC prognostic factors. The IMDC prognostic model was able to effectively stratify pRCC patients.",

author = "{Connor Wells}, John and Frede Donskov and Fraccon, {Anna P.} and Felice Pasini and Bjarnason, {Georg A.} and Benoit Beuselinck and Knox, {Jennifer J.} and Rha, {Sun Young} and Neeraj Agarwal and Bowman, {Isaac Alex} and Lee, {Jae Lyun} and Pal, {Sumanta K.} and Sandy Srinivas and {Scott Ernst}, Douglas and Vaishampayan, {Ulka N.} and Wood, {Lori A.} and Robin Simpson and {De Velasco}, Guillermo and Choueiri, {Toni K.} and Heng, {Daniel Y.C.}",

note = "Publisher Copyright: {\textcopyright} 2017 The Authors. Cancer Medicine published by John Wiley & Sons Ltd.",

year = "2017",

month = may,

doi = "10.1002/cam4.1048",

language = "English",

volume = "6",

pages = "902--909",

journal = "Cancer medicine",

issn = "2045-7634",

publisher = "John Wiley and Sons Ltd",

number = "5",

}

Connor Wells, J, Donskov, F, Fraccon, AP, Pasini, F, Bjarnason, GA, Beuselinck, B, Knox, JJ, Rha, SY, Agarwal, N, Bowman, IA, Lee, JL, Pal, SK, Srinivas, S, Scott Ernst, D, Vaishampayan, UN, Wood, LA, Simpson, R, De Velasco, G, Choueiri, TK & Heng, DYC 2017, 'Characterizing the outcomes of metastatic papillary renal cell carcinoma', Cancer medicine, vol. 6, no. 5, pp. 902-909. https://doi.org/10.1002/cam4.1048

TY - JOUR

T1 - Characterizing the outcomes of metastatic papillary renal cell carcinoma

AU - Connor Wells, John

AU - Donskov, Frede

AU - Fraccon, Anna P.

AU - Pasini, Felice

AU - Bjarnason, Georg A.

AU - Beuselinck, Benoit

AU - Knox, Jennifer J.

AU - Rha, Sun Young

AU - Agarwal, Neeraj

AU - Bowman, Isaac Alex

AU - Lee, Jae Lyun

AU - Pal, Sumanta K.

AU - Srinivas, Sandy

AU - Scott Ernst, Douglas

AU - Vaishampayan, Ulka N.

AU - Wood, Lori A.

AU - Simpson, Robin

AU - De Velasco, Guillermo

AU - Choueiri, Toni K.

AU - Heng, Daniel Y.C.

PY - 2017/5

Y1 - 2017/5

N2 - Outcomes of metastatic papillary renal cell carcinoma (pRCC) patients are poorly characterized in the era of targeted therapy. A total of 5474 patients with metastatic renal cell carcinoma (mRCC) in the International mRCC Database Consortium (IMDC) were retrospectively analyzed. Outcomes were compared between clear cell (ccRCC; n = 5008) and papillary patients (n = 466), and recorded type I and type II papillary patients (n = 30 and n = 165, respectively). Overall survival (OS), progression-free survival (PFS), and overall response rate (ORR) favored ccRCC over pRCC. OS was 8 months longer in ccRCC patients and the hazard ratio of death was 0.71 for ccRCC patients. No differences in PFS or ORR were detected between type I and II PRCC in this limited dataset. The median OS for type I pRCC was 20.0 months while the median OS for type II was 12.6 months (P = 0.096). The IMDC prognostic model was able to stratify pRCC patients into favorable risk (OS = 34.1 months), intermediate risk (OS = 17.0 months), and poor-risk groups (OS = 6.0 months). pRCC patient outcomes were inferior to ccRCC, even after controlling for IMDC prognostic factors. The IMDC prognostic model was able to effectively stratify pRCC patients.

AB - Outcomes of metastatic papillary renal cell carcinoma (pRCC) patients are poorly characterized in the era of targeted therapy. A total of 5474 patients with metastatic renal cell carcinoma (mRCC) in the International mRCC Database Consortium (IMDC) were retrospectively analyzed. Outcomes were compared between clear cell (ccRCC; n = 5008) and papillary patients (n = 466), and recorded type I and type II papillary patients (n = 30 and n = 165, respectively). Overall survival (OS), progression-free survival (PFS), and overall response rate (ORR) favored ccRCC over pRCC. OS was 8 months longer in ccRCC patients and the hazard ratio of death was 0.71 for ccRCC patients. No differences in PFS or ORR were detected between type I and II PRCC in this limited dataset. The median OS for type I pRCC was 20.0 months while the median OS for type II was 12.6 months (P = 0.096). The IMDC prognostic model was able to stratify pRCC patients into favorable risk (OS = 34.1 months), intermediate risk (OS = 17.0 months), and poor-risk groups (OS = 6.0 months). pRCC patient outcomes were inferior to ccRCC, even after controlling for IMDC prognostic factors. The IMDC prognostic model was able to effectively stratify pRCC patients.

UR - http://www.scopus.com/inward/record.url?scp=85017533875&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85017533875&partnerID=8YFLogxK

U2 - 10.1002/cam4.1048

DO - 10.1002/cam4.1048

M3 - Article

C2 - 28414866

AN - SCOPUS:85017533875

SN - 2045-7634

VL - 6

SP - 902

EP - 909

JO - Cancer medicine

JF - Cancer medicine

IS - 5

ER -

Characterizing the outcomes of metastatic papillary renal cell carcinoma

Abstract

Bibliographical note

All Science Journal Classification (ASJC) codes

UN SDGs

Access to Document

Other files and links

Fingerprint

Cite this